Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
Metrics to compare | 2629 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2629PeersSector | |
---|---|---|---|---|
P/E Ratio | −11.9x | −1.7x | −0.5x | |
PEG Ratio | 0.37 | −0.11 | 0.00 | |
Price/Book | - | 3.0x | 2.6x | |
Price / LTM Sales | 54.1x | 81.9x | 3.3x | |
Upside (Analyst Target) | - | 551.8% | 43.5% | |
Fair Value Upside | Unlock | 1.2% | 6.9% | Unlock |